---
title: "Crinetics Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.73 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285613825.md"
datetime: "2026-05-07T20:34:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285613825.md)
  - [en](https://longbridge.com/en/news/285613825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285613825.md)
---

# Crinetics Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.73 M

Revenue: As of FY2026 Q1, the actual value is USD 10.73 M, beating the estimate of USD 8.517 M.

EPS: As of FY2026 Q1, the actual value is USD -1.23, missing the estimate of USD -1.2227.

#### Segment Revenue

Crinetics Pharmaceuticals, Inc. reported total revenue of $10.7 million for the first quarter ended March 31, 2026, a significant increase from $0.4 million for the same period in 2025 . This total includes $10.3 million in net product revenue from the U.S. commercial launch of PALSONIFY, which is up from $5.4 million in net product revenue reported in the fourth quarter of 2025 . Collaboration and license revenue was $0.4 million for the first quarter of 2026, compared to $0.4 million in the first quarter of 2025 .

#### Operational Metrics

-   **Cost of Product Revenue**: Cost of product revenue was $0.2 million for the first quarter ended March 31, 2026, primarily related to distribution, packaging, and fulfillment of PALSONIFY . This is an increase from $0 million for the same period in 2025 .
-   **Research and Development (R&D) Expenses**: R&D expenses were $100.1 million for the first quarter ended March 31, 2026, compared to $76.2 million for the same period in 2025 . This also represents an increase from $85.1 million in the quarter ended December 31, 2025, driven by the advancement of clinical and preclinical programs, including the ramp-up of ongoing Phase 3 trials and the initiation of the Phase 2⁄3 pediatric study of atumelnant in CAH .
-   **Selling, General and Administrative (SG&A) Expenses**: SG&A expenses were $50.8 million for the first quarter ended March 31, 2026, compared to $35.5 million for the same period in 2025 . This increase reflects investments in corporate infrastructure as the company transitions to a commercial stage . SG&A expenses were $53.7 million in the quarter ended December 31, 2025, with the fluctuation compared to the prior quarter reflecting the timing of commercial investment .
-   **Total Operating Expenses**: Total operating expenses were $151.1 million for the first quarter ended March 31, 2026, compared to $111.8 million for the same period in 2025 .
-   **Loss from Operations**: Loss from operations was - $140.4 million for the first quarter ended March 31, 2026, compared to - $111.4 million for the same period in 2025 .
-   **Net Loss**: Net loss was - $127.8 million for the first quarter ended March 31, 2026, compared to a net loss of - $96.8 million for the same period in 2025 .

#### Cash and Investments

Cash, cash equivalents, and investment securities totaled $1.3 billion as of March 31, 2026, an increase from $1.0 billion as of December 31, 2025 . This total includes net proceeds of $380 million from a January 2026 public equity offering .

#### Unique Operational Metrics

-   **PALSONIFY Enrollment Forms**: Crinetics Pharmaceuticals, Inc. received 232 enrollment forms for PALSONIFY during the first quarter of 2026 .
-   **Unique Prescribers**: The company saw continued growth in PALSONIFY prescribers, with 263 unique healthcare providers having prescribed PALSONIFY within the first two quarters of launch .
-   **Reimbursed Therapy**: Approximately 70% of patients treated with PALSONIFY at the end of the first quarter of 2026 were on reimbursed therapy .

#### Outlook / Guidance

Crinetics Pharmaceuticals, Inc. expects 2026 GAAP operating expenses to range between $600 million to $650 million . Non-GAAP operating expenses are projected to be between $480 million to $520 million for 2026, excluding cost of product revenue, stock-based compensation, depreciation, and amortization . The company notes that reconciliation of forward-looking non-GAAP operating expenses to GAAP is not provided due to the difficulty in predicting certain excluded items .

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)
- [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)